

# Joel R Lexchin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/57761/publications.pdf>

Version: 2024-02-01

255  
papers

8,781  
citations

101384

36  
h-index

56606

83  
g-index

259  
all docs

259  
docs citations

259  
times ranked

7395  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmaceutical industry sponsorship and research outcome and quality: systematic review. <i>BMJ: British Medical Journal</i> , 2003, 326, 1167-1170.	2.4	1,733
2	Industry sponsorship and research outcome. <i>The Cochrane Library</i> , 2017, 2017, MR000033.	1.5	772
3	Industry sponsorship and research outcome. , 2012, 12, MR000033.		642
4	Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. <i>PLoS Medicine</i> , 2010, 7, e1000352.	3.9	385
5	The cost of drug development: A systematic review. <i>Health Policy</i> , 2011, 100, 4-17.	1.4	379
6	The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. <i>PLoS Medicine</i> , 2008, 5, e1.	3.9	343
7	Physician Awareness of Drug Cost: A Systematic Review. <i>PLoS Medicine</i> , 2007, 4, e283.	3.9	203
8	Pharmaceutical research and development: what do we get for all that money?. <i>BMJ, The</i> , 2012, 345, e4348-e4348.	3.0	168
9	Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence. <i>International Journal of Health Services</i> , 2004, 34, 101-122.	1.2	160
10	The pharmaceutical industry as a medicines provider. <i>Lancet, The</i> , 2002, 360, 1590-1595.	6.3	133
11	Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. <i>Science and Engineering Ethics</i> , 2012, 18, 247-261.	1.7	130
12	Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1008.	3.8	121
13	Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 590-600.	0.4	112
14	Surrogate Outcomes in Clinical Trials. <i>JAMA Internal Medicine</i> , 2013, 173, 611.	2.6	109
15	Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No. <i>Journal of Public Policy and Marketing</i> , 2002, 21, 194-201.	2.2	106
16	Industry sponsorship and research outcome: systematic review with meta-analysis. <i>Intensive Care Medicine</i> , 2018, 44, 1603-1612.	3.9	97
17	Sponsorship bias in clinical research. <i>International Journal of Risk and Safety in Medicine</i> , 2012, 24, 233-242.	0.3	95
18	The effect of generic competition on the price of brand-name drugs. <i>Health Policy</i> , 2004, 68, 47-54.	1.4	79

#	ARTICLE	IF	CITATIONS
19	Physician awareness of diagnostic and nondrug therapeutic costs: A systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 158-165.	0.2	79
20	Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States. <i>Journal of General Internal Medicine</i> , 2013, 28, 1368-1375.	1.3	79
21	Pathways to independence: towards producing and using trustworthy evidence. <i>BMJ, The</i> , 2019, 367, l6576.	3.0	79
22	Doctors and Detailers: Therapeutic Education or Pharmaceutical Promotion?. <i>International Journal of Health Services</i> , 1989, 19, 663-679.	1.2	78
23	Commercial influence and the content of medical journals. <i>BMJ: British Medical Journal</i> , 2006, 332, 1444-1447.	2.4	77
24	Bigger and Better: How Pfizer Redefined Erectile Dysfunction. <i>PLoS Medicine</i> , 2006, 3, e132.	3.9	67
25	Drug withdrawals from the Canadian market for safety reasons, 1963-2004. <i>Cmaj</i> , 2005, 172, 765-767.	0.9	61
26	New Drugs and Safety. <i>Archives of Internal Medicine</i> , 2012, 172, 1680.	4.3	61
27	Foreign free riders and the high price of US medicines. <i>BMJ: British Medical Journal</i> , 2005, 331, 958-960.	2.4	59
28	A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. <i>Health Policy</i> , 2015, 119, 802-813.	1.4	51
29	Implications of Pharmaceutical Industry Funding on Clinical Research. <i>Annals of Pharmacotherapy</i> , 2005, 39, 194-197.	0.9	50
30	Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. <i>BMJ, The</i> , 2020, 369, m1505.	3.0	49
31	Observational Evidence of For-Profit Delivery and Inferior Nursing Home Care: When Is There Enough Evidence for Policy Change?. <i>PLoS Medicine</i> , 2016, 13, e1001995.	3.9	48
32	Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. <i>BMJ, The</i> , 2012, 345, e5155-e5155.	3.0	46
33	The effect of early in-hospital medication review on health outcomes: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 51-61.	1.1	44
34	Is there still a role for spontaneous reporting of adverse drug reactions?. <i>Cmaj</i> , 2006, 174, 191-192.	0.9	43
35	Prohibiting or "managing" conflict of interest? A review of policies and procedures in three European drug regulation agencies. <i>Social Science and Medicine</i> , 2010, 70, 643-647.	1.8	41
36	Medicines Information and the Regulation of the Promotion of Pharmaceuticals. <i>Science and Engineering Ethics</i> , 2019, 25, 1167-1192.	1.7	39

#	ARTICLE	IF	CITATIONS
37	Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. PLoS ONE, 2013, 8, e68633.	1.1	38
38	“Adaptive pathways” to drug authorisation: adapting to industry?. BMJ, The, 2016, 354, i4437.	3.0	38
39	Ten Principles for More Conservative, Care-Full Diagnosis. Annals of Internal Medicine, 2018, 169, 643.	2.0	37
40	Improving the Appropriateness of Physician Prescribing. International Journal of Health Services, 1998, 28, 253-267.	1.2	36
41	Why do cancer drugs get such an easy ride?. BMJ, The, 2015, 350, h2068-h2068.	3.0	36
42	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 840-851.	0.4	36
43	Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. British Journal of Clinical Pharmacology, 2015, 79, 847-859.	1.1	35
44	Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations. PLoS Medicine, 2006, 3, e451.	3.9	34
45	Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts. Globalization and Health, 2019, 15, 78.	2.4	33
46	Poor Reporting of Scientific Leadership Information in Clinical Trial Registers. PLoS ONE, 2008, 3, e1610.	1.1	32
47	Legislative regulation and ethical governance of medical research in different European Union countries. Journal of Medical Ethics, 2014, 40, 409-413.	1.0	31
48	The costs of coronavirus vaccines and their pricing. Journal of the Royal Society of Medicine, 2021, 114, 502-504.	1.1	31
49	Adverse drug events: counting is not enough, action is needed. Medical Journal of Australia, 2006, 184, 315-316.	0.8	30
50	Health Canada's use of its priority review process for new drugs: a cohort study. BMJ Open, 2015, 5, e006816-e006816.	0.8	30
51	The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries. Global Social Policy, 2018, 18, 7-27.	1.0	29
52	The danger of imperfect regulation: OxyContin use in the United States and Canada. International Journal of Risk and Safety in Medicine, 2011, 23, 233-240.	0.3	28
53	Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. Cmaj, 2020, 192, E617-E625.	0.9	28
54	Pharmaceuticals, Patents, and Politics: Canada and Bill C-22. International Journal of Health Services, 1993, 23, 147-160.	1.2	27

#	ARTICLE	IF	CITATIONS
55	Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase. BMC Health Services Research, 2016, 16, 383.	0.9	26
56	A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough. Journal of General Internal Medicine, 2021, 36, 3194-3198.	1.3	25
57	Medicine reimbursement recommendations in Canada, Australia, and Scotland. American Journal of Managed Care, 2008, 14, 581-8.	0.8	25
58	CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs. Globalization and Health, 2014, 10, 30.	2.4	24
59	Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST. Annals of Family Medicine, 2017, 15, 413-418.	0.9	24
60	Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis. Journal of Pharmaceutical Policy and Practice, 2018, 11, 5.	1.1	24
61	Pharmacovigilance in Europe and North America: Divergent approaches. Social Science and Medicine, 2012, 75, 165-170.	1.8	23
62	Pharmaceutical Promotion in Canada: Convince Them or Confuse Them. International Journal of Health Services, 1987, 17, 77-89.	1.2	22
63	'Linkage' pharmaceutical evergreening in Canada and Australia. Australia and New Zealand Health Policy, 2007, 4, 8.	2.2	22
64	Models for financing the regulation of pharmaceutical promotion. Globalization and Health, 2012, 8, 24.	2.4	22
65	The Need to Systematically Evaluate Clinical Practice Guidelines. Journal of the American Board of Family Medicine, 2016, 29, 644-648.	0.8	22
66	After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. Health Policy, 1997, 40, 69-80.	1.4	21
67	Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. JAMA Internal Medicine, 2019, 179, 982.	2.6	21
68	Assessing the quality of drug detailing. Journal of Clinical Epidemiology, 2002, 55, 825-832.	2.4	19
69	Intellectual Property Rights and the Canadian Pharmaceutical Marketplace: Where Do We Go from Here?. International Journal of Health Services, 2005, 35, 237-256.	1.2	19
70	From <i>caveat emptor</i> to <i>caveat venditor</i> : time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice, 2014, 20, 809-812.	0.9	19
71	Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychotherapy and Psychosomatics, 2017, 86, 168-170.	4.0	19
72	Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis. BMJ Open, 2018, 8, e023605.	0.8	19

#	ARTICLE	IF	CITATIONS
73	Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews. BMC Health Services Research, 2013, 13, 88.	0.9	18
74	The Pharmaceutical Industry in Contemporary Capitalism. Monthly Review, 0, , 37-50.	0.3	18
75	Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. BMJ: British Medical Journal, 2018, 361, k1039.	2.4	17
76	Effects of restrictive formularies in the ambulatory care setting. American Journal of Managed Care, 2002, 8, 69-76.	0.8	17
77	Transparency in drug regulation: Mirage or oasis?. Cmaj, 2004, 171, 1363-1365.	0.9	16
78	Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. Cmaj, 2006, 174, 1120-1121.	0.9	16
79	The association between a journal's source of revenue and the drug recommendations made in the articles it publishes. Cmaj, 2011, 183, 544-548.	0.9	16
80	International comparison of assessments of pharmaceutical innovation. Health Policy, 2012, 105, 221-225.	1.4	16
81	The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia. International Journal of Health Services, 2016, 46, 597-613.	1.2	16
82	The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis. CMAJ Open, 2017, 5, E724-E728.	1.1	16
83	Financial costs associated with monopolies on biologic medicines in Australia. Australian Health Review, 2019, 43, 36.	0.5	16
84	One step forward, one step sideways? Expanding research capacity for neglected diseases. BMC International Health and Human Rights, 2010, 10, 20.	2.5	15
85	What do Canadians think about physicianâ€“pharmaceutical industry interactions?. Health Policy, 2013, 112, 255-263.	1.4	15
86	Can reporting of adverse drug reactions create safer systems while improving health data?. Cmaj, 2015, 187, 789-790.	0.9	15
87	Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study. PLoS ONE, 2019, 14, e0212399.	1.1	15
88	Indicators for measuring mental health: towards better surveillance. Healthcare Policy, 2009, 5, e177-86.	0.3	15
89	A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation. International Journal of Risk and Safety in Medicine, 2014, 26, 213-225.	0.3	14
90	Notice of compliance with conditions: a policy in limbo. Healthcare Policy, 2007, 2, 114-22.	0.3	14

#	ARTICLE	IF	CITATIONS
91	Prescribing and Drug Costs in the Province of Ontario. <i>International Journal of Health Services</i> , 1992, 22, 471-487.	1.2	13
92	Who Needs Faster Drug Approval Times in Canada: The Public or the Industry?. <i>International Journal of Health Services</i> , 1994, 24, 253-264.	1.2	12
93	Beyond patents: The GAVI Alliance, AMCs and improving immunization coverage through public sector vaccine production in the global south. <i>Hum Vaccin</i> , 2011, 7, 291-292.	2.4	12
94	Coverage with Evidence Development for Pharmaceuticals: A Policy in Evolution?. <i>International Journal of Health Services</i> , 2011, 41, 337-354.	1.2	12
95	Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons. <i>Pharmaceutical Medicine</i> , 2016, 30, 277-289.	1.0	12
96	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1424-1442.	2.3	12
97	Achieving greater independence from commercial influence in research. <i>BMJ, The</i> , 2021, 372, n370.	3.0	12
98	How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. <i>Open Medicine</i> , 2014, 8, e14-9.	1.5	12
99	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. <i>Healthcare Policy</i> , 2016, 12, 18-36.	0.3	12
100	The Medical Profession and the Pharmaceutical Industry: An Unhealthy Alliance. <i>International Journal of Health Services</i> , 1988, 18, 603-616.	1.2	11
101	Pharmaceutical Promotion in the Third World. <i>Journal of Drug Issues</i> , 1992, 22, 417-453.	0.6	11
102	Direct-To-Consumer Advertising. <i>Disease Management and Health Outcomes</i> , 1999, 5, 273-283.	0.3	11
103	National Evaluation of Policies on Individual Financial Conflicts of Interest in Canadian Academic Health Science Centers. <i>Journal of General Internal Medicine</i> , 2008, 23, 1896-1903.	1.3	11
104	Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?. <i>BMC Health Services Research</i> , 2011, 11, 64.	0.9	11
105	The FDA's new clothes. <i>BMJ, The</i> , 2015, 351, h4897.	3.0	11
106	Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. <i>Systematic Reviews</i> , 2020, 9, 77.	2.5	11
107	Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. <i>International Journal of Health Services</i> , 2021, 51, 5-13.	1.2	11
108	Relationship Between Pharmaceutical Company User Fees and Drug Approvals in Canada and Australia: A Hypothesis-Generating Study. <i>Annals of Pharmacotherapy</i> , 2006, 40, 2216-2222.	0.9	10

#	ARTICLE	IF	CITATIONS
109	Quality and Quantity of Information in Summary Basis of Decision Documents Issued by Health Canada. PLoS ONE, 2014, 9, e92038.	1.1	10
110	The Miracle of the Empty Beds: A History of Tuberculosis in Canada. Labour/Le Travail, 1980, 6, 233.	0.0	9
111	Canadian Marketing Codes: How Well are They Controlling Pharmaceutical Promotion?. International Journal of Health Services, 1994, 24, 91-104.	1.2	9
112	Introduction of direct-to-consumer advertising of prescription drugs in Canada: An opinion survey on regulatory policy. Research in Social and Administrative Pharmacy, 2005, 1, 310-330.	1.5	9
113	How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study. Healthcare Policy, 2016, 12, 65-75.	0.3	9
114	We need to mandate drug cost transparency on electronic medical records. Cmaj, 2017, 189, E1541-E1542.	0.9	9
115	A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States 2007 to 2016. Pharmacoepidemiology and Drug Safety, 2020, 29, 1054-1063.	0.9	9
116	Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study. BMJ Open, 2020, 10, e034993.	0.8	9
117	Differences in the Volume of Pharmaceutical Advertisements between Print General Medical Journals. PLoS ONE, 2014, 9, e84790.	1.1	9
118	Everyday experiences of implicit rationing: comparing the voices of nurses in California and British Columbia. Sociology of Health and Illness, 2001, 23, 633-653.	1.1	8
119	Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary. Health Policy, 2009, 91, 142-147.	1.4	8
120	Harmony in Drug Regulation, but Who's Calling the Tune? An Examination of Regulatory Harmonization in Health Canada. International Journal of Health Services, 2012, 42, 119-136.	1.2	8
121	Off-Label Drug Use. American Journal of Medical Quality, 2016, 31, 285-285.	0.2	8
122	Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study. BMJ Open, 2018, 8, e020377.	0.8	8
123	A call to mandate patient access to personal primary care medical records across Canada. Cmaj, 2018, 190, E869-E870.	0.9	8
124	Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. BMJ Open, 2020, 10, e035633.	0.8	8
125	Affordable Biologics for All. JAMA Network Open, 2020, 3, e204753.	2.8	8
126	Pharmaceuticals as a market for "celebrations": Theory and practice. Social Science and Medicine, 2021, 268, 113368.	1.8	8



#	ARTICLE	IF	CITATIONS
127	How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study. Healthcare Policy, 2016, 12, 65-75.	0.3	8
128	Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect. British Medical Bulletin, 2015, 116, ldv042.	2.7	7
129	Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations. International Journal of Risk and Safety in Medicine, 2017, 29, 1-16.	0.3	7
130	Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study. Value in Health, 2017, 20, 1139-1142.	0.1	7
131	Nursing Home Physicians Discuss Caring for Elderly Residents: An Exploratory Study. Canadian Journal on Aging, 2018, 37, 133-144.	0.6	7
132	The "pharmaceuticalisation" of life. BMJ: British Medical Journal, 2019, 365, l1972.	2.4	7
133	Canada finally opens up data on new drugs and devices. BMJ: British Medical Journal, 2019, 365, l1825.	2.4	7
134	An International Mapping of Medical Care in Nursing Homes. Health Services Insights, 2019, 12, 117863291882508.	0.6	7
135	Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis. International Journal of Health Services, 2019, 49, 294-305.	1.2	7
136	A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. Health Policy, 2006, 79, 214-220.	1.4	6
137	Clinical Trials in Canada: Whose Interests are Paramount?. International Journal of Health Services, 2008, 38, 525-542.	1.2	6
138	Statistics in drug advertising: what they reveal is suggestive what they hide is vital. International Journal of Clinical Practice, 2010, 64, 1015-1018.	0.8	6
139	Provincial Drug Plan Officials' Views of the Canadian Drug Safety System. Journal of Health Politics, Policy and Law, 2013, 38, 545-571.	0.9	6
140	Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?. Health Policy, 2016, 120, 890-891.	1.4	6
141	Declarations of interest by members of Health Canada's special advisory committees and panels: a descriptive study. CMAJ Open, 2019, 7, E334-E340.	1.1	6
142	Secret safety warnings on medicines: A case study of information access requests. Pharmacoepidemiology and Drug Safety, 2019, 28, 551-555.	0.9	6
143	Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study. BMJ Open, 2019, 9, e030750.	0.8	6
144	Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant?. Alcohol and Alcoholism, 2020, 55, 49-50.	0.9	6

#	ARTICLE	IF	CITATIONS
145	Restoring the Bacloville trial: efficacy and harms. <i>Addiction</i> , 2020, 115, 2184-2186.	1.7	6
146	Combating corruption in the pharmaceutical arena. <i>Indian Journal of Medical Ethics</i> , 2018, 3, 234-239.	0.2	6
147	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. <i>BMJ Quality and Safety</i> , 2022, 31, 179-190.	1.8	6
148	CJEM and pharmaceutical advertisements: it's time for an end. <i>Canadian Journal of Emergency Medicine</i> , 2009, 11, 375-379.	0.5	5
149	Pharmaceutical Research and Development: What Do We Get for All that Money?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
150	Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study. <i>BMJ Open</i> , 2014, 4, e004289.	0.8	5
151	Why are there deadly drugs?. <i>BMC Medicine</i> , 2015, 13, 27.	2.3	5
152	Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care. <i>Health Policy</i> , 2018, 122, 250-255.	1.4	5
153	Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence. <i>Globalization and Health</i> , 2018, 14, 86.	2.4	5
154	Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2549-2556.	1.1	5
155	Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsa083.	0.8	5
156	Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 475-479.	2.5	5
157	Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey. <i>Open Medicine</i> , 2010, 4, e134-8.	1.5	5
158	The siren call of new drugs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2003, 3, 513-515.	0.7	4
159	Drug safety and Health Canada. <i>International Journal of Risk and Safety in Medicine</i> , 2010, 22, 41-53.	0.3	4
160	Canada and access to medicines in developing countries: intellectual property rights first. <i>Globalization and Health</i> , 2013, 9, 42.	2.4	4
161	Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia. <i>International Journal of Health Services</i> , 2020, 50, 166-172.	1.2	4
162	Time to market for drugs approved in Canada between 2014 and 2018: an observational study. <i>BMJ Open</i> , 2021, 11, e047557.	0.8	4

#	ARTICLE	IF	CITATIONS
163	How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study. PLoS ONE, 2020, 15, e0240966.	1.1	4
164	Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care Between Patients and Providers. Healthcare Policy, 2019, 14, 21-27.	0.3	4
165	The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena. Medicine and Law, 2007, 26, 417-30.	0.0	4
166	After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada. International Journal of Health Services, 2022, 52, 341-346.	1.2	4
167	Double standards: double jeopardy. Pharmacoepidemiology and Drug Safety, 2000, 9, 289-290.	0.9	3
168	PHARMACEUTICAL PROMOTION IN NEW ZEALAND. Community Health Studies, 1988, 12, 264-272.	0.0	3
169	Economics and industry do not mean ethical conduct in clinical trials. Journal of Pharmaceutical Policy and Practice, 2013, 6, 11.	1.1	3
170	Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study. CMAJ Open, 2015, 3, E286-E291.	1.1	3
171	Publication of confirmatory studies required by Health Canada for drugs approved under a Notice of Compliance with conditions: a cohort study. CMAJ Open, 2017, 5, E295-E300.	1.1	3
172	Canadian status of off-label drugs to avoid in 2017: a descriptive analysis. CMAJ Open, 2018, 6, E430-E435.	1.1	3
173	Innovation and off-label use, the French case and more. British Journal of Clinical Pharmacology, 2019, 85, 2446-2447.	1.1	3
174	Time to Marketing of Generic Drugs After Patent Expiration in Canada. JAMA Network Open, 2021, 4, e211143.	2.8	3
175	Letters to the Editor: Click, click: the internet and prescription drugs. Australian Prescriber, 2000, 23, 73-74.	0.5	3
176	Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study. Healthcare Policy, 2019, 14, 10-18.	0.3	3
177	New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?. Canadian Family Physician, 2002, 48, 1487-92.	0.1	3
178	Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary. Healthcare Policy, 2010, 5, 26-36.	0.3	3
179	Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship. Healthcare Policy, 2013, 9, 22-9.	0.3	3
180	COVID-19 Vaccine Task Force and Conflicts of Interest. Healthcare Policy, 2022, 17, 20-27.	0.3	3

#	ARTICLE	IF	CITATIONS
181	Hear No Secrets, See No Secrets, Speak No Secrets: Secrecy in the Canadian Drug Approval System. <i>International Journal of Health Services</i> , 1999, 29, 167-178.	1.2	2
182	Drug Approval Times and User Fees. <i>Pharmaceutical Medicine</i> , 2008, 22, 1-11.	1.0	2
183	Pharmaceutical Sales Representatives and Patient Safety. <i>Journal of General Internal Medicine</i> , 2013, 28, 1395-1395.	1.3	2
184	Drug prices: How do we get to a better place?. <i>Cmaj</i> , 2017, 189, E792-E793.	0.9	2
185	Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. <i>International Journal of Health Services</i> , 2018, 48, 702-715.	1.2	2
186	Drug Promotion in India Since 2000: Problems Remain. <i>International Journal of Health Services</i> , 2021, 51, 392-403.	1.2	2
187	Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	2
188	Of Money And Trust In Biomedical Care. <i>Mens Sana Monographs</i> , 2007, 5, 7.	0.2	2
189	Are drugs too expensive in Canada? Yes. <i>Canadian Family Physician</i> , 2006, 52, 573-6, 578-81.	0.1	2
190	Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort?. <i>Healthcare Policy</i> , 2010, 5, 40-8.	0.3	2
191	Antidepressants are not safe during pregnancy and in women of childbearing age. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2447-2448.	1.1	2
192	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. <i>Drug Safety</i> , 2022, , 1.	1.4	2
193	To the editor:. <i>Journal of Emergency Medicine</i> , 2001, 20, 415.	0.3	1
194	Safeguarding the Quality of Clinical Research. <i>AMA Journal of Ethics</i> , 2003, 5, 216.	0.4	1
195	Is Australia's National Medicines Policy Failing? the Case of Cox-2 Inhibitors. <i>International Journal of Health Services</i> , 2007, 37, 735-744.	1.2	1
196	Regulating Drugs for Effectiveness and Safety: A Public Health Perspective. <i>Medical Care</i> , 2007, 45, 911.	1.1	1
197	Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandinos. <i>Social Science and Medicine</i> , 2010, 70, 972-973.	1.8	1
198	Of money and trust in medical care redux. <i>Mens Sana Monographs</i> , 2012, 10, 143.	0.2	1

#	ARTICLE	IF	CITATIONS
199	Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: A cohort study. <i>International Journal of Risk and Safety in Medicine</i> , 2015, 27, 135-142.	0.3	1
200	The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
201	Medicines Save, Medicines Kill. <i>Drug Safety</i> , 2017, 40, 457-459.	1.4	1
202	Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis. <i>BMJ Open</i> , 2017, 7, e018372.	0.8	1
203	The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system. <i>The Cochrane Library</i> , 2019, , .	1.5	1
204	National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. <i>Obstetrics and Gynecology</i> , 2019, 134, 1115-1117.	1.2	1
205	Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature. <i>Health Policy</i> , 2020, 124, 231-238.	1.4	1
206	Financial conflict of interest among clinical practice guideline-producing organisations. <i>British Journal of General Practice</i> , 2020, 70, 530-531.	0.7	1
207	The Rise and Fall of the Neurotic Housewife: Patient Sex in Psychotropic Drug Advertising to Physicians 1946-1990. <i>International Journal of Health Services</i> , 2020, 50, 292-298.	1.2	1
208	The "Nuts and Bolts" of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse. <i>Journal of General Internal Medicine</i> , 2020, 35, 3730-3732.	1.3	1
209	Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis. <i>International Journal of Risk and Safety in Medicine</i> , 2021, 32, 331-341.	0.3	1
210	Stop the Merry-Go-Round. <i>HealthcarePapers</i> , 2004, 4, 29-34.	0.2	1
211	The Timeliness of New Drug Approvals in Canada: A Rejoinder. <i>International Journal of Health Services</i> , 1995, 25, 167-171.	1.2	1
212	It's Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada". <i>International Journal of Health Policy and Management</i> , 2020, 9, 528-530.	0.5	1
213	Rebuttal: are drugs too expensive in Canada?. <i>Canadian Family Physician</i> , 2006, 52, 841-2, 843-5.	0.1	1
214	Different conclusions about memantine. <i>Canadian Family Physician</i> , 2007, 53, 403-4; author reply 404.	0.1	1
215	Complete dissociation from the health care and pharmaceutical industry. <i>Canadian Family Physician</i> , 2015, 61, 668-9.	0.1	1
216	Can direct-to-consumer advertising of prescription drugs be effectively regulated?. <i>New Zealand Medical Journal</i> , 2019, 132, 59-65.	0.5	1

#	ARTICLE	IF	CITATIONS
217	Pharmaceutical Company Payments to Healthcare Professionals and Healthcare Organizations in Canada: An Observational Study. <i>Healthcare Policy</i> , 2022, 17, 42-48.	0.3	1
218	National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e055287.	0.8	1
219	Industry involvement in clinical practice guidelines. <i>Canadian Family Physician</i> , 2021, 67, 721.4-724.	0.1	1
220	Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study. <i>Australian Health Review</i> , 2022, 46, 309-315.	0.5	1
221	Sponsorship of Canadian Professional Medical Societies by Drug, Medical Device and Medical Technology Companies: a Cross-sectional Study. <i>Journal of General Internal Medicine</i> , 2022, , .	1.3	1
222	Esophageal detector devices and children. <i>Canadian Journal of Emergency Medicine</i> , 1999, 1, 162-163.	0.5	0
223	Educating Health Professionals about Drug and Device Promotion: Authors' Reply. <i>PLoS Medicine</i> , 2007, 4, e88.	3.9	0
224	Le JCMU et les publicités pharmaceutiques : il est temps d'arrêter de le faire. <i>Canadian Journal of Emergency Medicine</i> , 2009, 11, 380-384.	0.5	0
225	Ban Drug Advertisements. <i>Canadian Journal of Emergency Medicine</i> , 2011, 13, 297.	0.5	0
226	Who should fund CME?. <i>Canadian Journal of Emergency Medicine</i> , 2013, 15, 133.	0.5	0
227	Opioid abuse. <i>Cmaj</i> , 2013, 185, 418.2-418.	0.9	0
228	Skilled use of the media by vested interests to promote drugs and other health products. <i>BMJ</i> , The, 2016, 352, i1179.	3.0	0
229	Hippocrates and Targin. <i>Cmaj</i> , 2016, 188, 1262.2-1262.	0.9	0
230	Myths and Realities About Why Prescription Drug Prices in the United States Are So High. <i>Pharmaceutical Medicine</i> , 2017, 31, 143-148.	1.0	0
231	Priority reviews: innovation and safety. <i>Cmaj</i> , 2017, 189, E895-E895.	0.9	0
232	The Pharmaceutical Industry and the Canadian Government: Folie À Deux. <i>Healthcare Policy</i> , 2017, 13, 10-16.	0.3	0
233	Cost recovery by Health Canada and drug safety: a time-series analysis. <i>CMAJ Open</i> , 2018, 6, E471-E477.	1.1	0
234	Pharmaceutical Industry's "Initiated Postapproval Studies" Not Requested by the US FDA, Little Value, and Many Questions. <i>JAMA Network Open</i> , 2019, 2, e193392.	2.8	0

#	ARTICLE	IF	CITATIONS
235	Information and promotional strategies by pharmaceutical companies for clinicians. The Cochrane Library, 0, , .	1.5	0
236	COVID-19: still much to learn. Journal of the Royal Society of Medicine, 2020, 113, 244-244.	1.1	0
237	Who assigns value in value-based insurance design?. Cmaj, 2020, 192, E15-E15.	0.9	0
238	Information and promotional strategies by pharmaceutical companies for clinicians. The Cochrane Library, 2020, , .	1.5	0
239	The potential benefits of a national vaccine registry for Canada. Cmaj, 2021, 193, E808-E808.	0.9	0
240	Health Canada: optimizing transparency and its impact for patients. Cmaj, 2021, 193, E1503-E1503.	0.9	0
241	A sorry tale of unnecessary secrecy about medicine safety. Internal Medicine Journal, 2021, 51, 1765-1766.	0.5	0
242	Evolution of Physician-Industry Relationships in Producing Knowledge of Drug Therapy - Comparison of the United States and Finland. SSRN Electronic Journal, 0, , .	0.4	0
243	Health Canada's Proposal to Accelerate New Drug Reviews. Healthcare Policy, 2020, 15, 26-34.	0.3	0
244	A comparison of the Food and Drug Administration's and Health Canada's regulatory decisions about failed confirmatory trials for oncology drugs: an observational study. Journal of Pharmaceutical Policy and Practice, 2021, 14, 93.	1.1	0
245	Medications for obesity. Canadian Family Physician, 2008, 54, 848-9; author reply 849-50.	0.1	0
246	Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: no. Canadian Family Physician, 2011, 57, 871, 873, 875, 877; discussion e276, e278.	0.1	0
247	The term is misleading. Canadian Family Physician, 2018, 64, 792.	0.1	0
248	Direct-to-consumer advertising of prescription medications: what the Canadian medical trainee needs to know. Canadian Medical Education Journal, 2019, 10, e113-e116.	0.3	0
249	Engaging physicians to prescribe more cost-effectively: Blueprint for change. Canadian Family Physician, 2020, 66, 723-725.	0.1	0
250	Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada. International Journal of Health Policy and Management, 2021, , .	0.5	0
251	Title is missing!. , 2020, 15, e0240966.		0
252	Title is missing!. , 2020, 15, e0240966.		0

#	ARTICLE	IF	CITATIONS
253	Title is missing!. , 2020, 15, e0240966.		0
254	Title is missing!. , 2020, 15, e0240966.		0
255	Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study. JRSM Open, 2022, 13, 205427042211112.	0.2	0